1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 1, 04/Jan/2024
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.1.2300670
2024-01-04
2024-12-12
https://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.1.2300670
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/1/eurosurv-29-1-2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.1.2300670&mimeType=html&fmt=ahah

References

  1. Epiconcept. Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza. Paris: Epiconcept. [Accessed 6 Oct 2023]. Available from: https://www.epiconcept.fr/en/epidemio-project/vaccine-effectiveness-burden-and-impact-studies-vebis-of-covid-19-and-influenza
  2. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Euro Surveill. 2022;27(30):2200551.  https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200551  PMID: 35904059 
  3. Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, et al. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022. Influenza Other Respir Viruses. 2023;17(11):e13195.  https://doi.org/10.1111/irv.13195  PMID: 38019704 
  4. European Centre for Disease Prevention and Control (ECDC). Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries. Stockholm: ECDC; 30 Nov 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/interim-analysis-covid-19-vaccine-effectiveness-against-hospitalisation-and-death
  5. European Centre for Disease Prevention and Control (ECDC). Pilot protocol for a COVID-19 vaccine effectiveness study using health data registries: version 1.0. Stockholm: ECDC; 19 Sep 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-pilot-protocol-vaccine-effectiveness-study-using-health-data-registries
  6. European Centre for Disease Prevention and Control (ECDC). Protocol for a COVID-19 vaccine effectiveness study using health data registries. Stockholm: ECDC; 30 Jan 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/protocol-covid-19-vaccine-effectiveness-study-using-health-data-registries
  7. European Centre for Disease Prevention and Control (ECDC). Case definition for COVID-19. Stockholm: ECDC; 31 May 2023. Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
  8. Deeks J, Higgins J, Altman D. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane: 2023. Available from www.training.cochrane.org/handbook
  9. Lin DY, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of bivalent boosters against Omicron subvariants. N Engl J Med. 2023;388(19):1818-20.  https://doi.org/10.1056/NEJMc2302462  PMID: 37043647 
  10. Lau JJ, Cheng SMS, Leung K, Lee CK, Hachim A, Tsang LCH, et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat Med. 2023;29(2):348-57.  https://doi.org/10.1038/s41591-023-02219-5  PMID: 36652990 
  11. Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. Lancet Infect Dis. 2023;23(11):1235-43.  https://doi.org/10.1016/S1473-3099(23)00365-1  PMID: 37453440 
  12. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023;382:e075286.  https://doi.org/10.1136/bmj-2022-075286  PMID: 37491022 
  13. Grewal R, Buchan SA, Nguyen L, Nasreen S, Austin PC, Brown KA, et al. Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) Study. J Infect Dis. 2023:jiad419.  https://doi.org/10.1093/infdis/jiad419  PMID: 37798119 
  14. Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023;14(1):2800.  https://doi.org/10.1038/s41467-023-38435-3  PMID: 37193706 
  15. European Centre for Disease Prevention and Control (ECDC). Epidemiological update: COVID-19 transmission in the EU/EEA, SARS-CoV-2 variants, and public health considerations for Autumn 2023. Stockholm: ECDC; 7 Sep 2023. Available from: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-covid-19-transmission-eueea-sars-cov-2-variants-and-public
  16. Machado A, Kislaya I, Soares P, Magalhães S, Rodrigues AP, Franco R, et al. Bivalent mRNA vaccine effectiveness against COVID-19 infections, hospitalisations and deaths in Portugal: a cohort study based on electronic health records, September 2022 to May 2023. medRxiv. 2023:2023.09.05.23295025. Preprint. https://medrxiv.org/lookup/doi/10.1101/2023.09.05.23295025https://dx.doi.org/ https://doi.org/10.1101/2023.09.05.23295025 
  17. Fabiani M, Mateo-Urdiales A, Sacco C, Rota MC, Fotakis EA, Petrone D, et al. Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023. Euro Surveill. 2023;28(32):2300397.  https://doi.org/10.2807/1560-7917.ES.2023.28.32.2300397  PMID: 37561053 
  18. Lipsitch M. Challenges of vaccine effectiveness and waning studies. Clin Infect Dis. 2019;68(10):1631-3.  https://doi.org/10.1093/cid/ciy773  PMID: 30204853 
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Mario+Font%C3%A1n-Vela&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fontán-Vela Mario</a>, <a href="/search?value1=Esther+Kissling&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kissling Esther</a>, <a href="/search?value1=Nathalie+Nicolay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nicolay Nathalie</a>, <a href="/search?value1=Toon+Braeye&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Braeye Toon</a>, <a href="/search?value1=Izaak+Van+Evercooren&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Van Evercooren Izaak</a>, <a href="/search?value1=Christian++Holm+Hansen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Holm Hansen Christian </a>, <a href="/search?value1=Hanne-Dorthe+Emborg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Emborg Hanne-Dorthe</a>, <a href="/search?value1=Massimo+Fabiani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fabiani Massimo</a>, <a href="/search?value1=Alberto+Mateo-Urdiales&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mateo-Urdiales Alberto</a>, <a href="/search?value1=Ala%26apos%3Ba+AlKerwi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">AlKerwi Ala&apos;a</a>, <a href="/search?value1=Susanne+Schmitz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schmitz Susanne</a>, <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=Brechje+de+Gier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Gier Brechje</a>, <a href="/search?value1=Susan+Hahn%C3%A9&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hahné Susan</a>, <a href="/search?value1=Hinta+Meijerink&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meijerink Hinta</a>, <a href="/search?value1=Jostein+Starrfelt&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Starrfelt Jostein</a>, <a href="/search?value1=Baltazar+Nunes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nunes Baltazar</a>, <a href="/search?value1=Constantino+Caetano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Caetano Constantino</a>, <a href="/search?value1=Tarik+Derrough&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Derrough Tarik</a>, <a href="/search?value1=Anthony+Nardone&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nardone Anthony</a>, <a href="/search?value1=Susana+Monge&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Monge Susana</a>, <a href="/search?value1=VEBIS-Lot4+working+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">VEBIS-Lot4 working group</a></span>. Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(1):pii=2300670. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300670" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300670</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 24 Nov 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 11 Dec 2023 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.1.2300670
/content/10.2807/1560-7917.ES.2024.29.1.2300670
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error